Ana Florea, Lina Sy, Lei Qian, Bradley Ackerson, Yi Luo, Jun Wu, Yanjun Cheng, Jennifer Ku, Leticia Vega Daily, Harpreet Takhar, Jeannie Song, Elizabeth Chmielewski-Yee, O'Mareen Spence, Harry Seifert, Driss Oraichi, Hung Fu Tseng
We evaluated the vaccine effectiveness (VE) of two doses of recombinant zoster vaccine (RZV) against herpes zoster (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC). Chinese KPSC members were identified based on self-reported ethnicity or self-reported preferred spoken/written language. Those aged ≥50 years who received two doses of RZV 4 weeks to ≤ 6 months apart were matched 1:4 to RZV unvaccinated Chinese members and followed through June 2022; second doses were accrued 6/1/2018-12/31/2020...
December 31, 2024: Human Vaccines & Immunotherapeutics